Compare TRST & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRST | ABUS |
|---|---|---|
| Founded | 1902 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 834.0M | 929.6M |
| IPO Year | 1994 | 2008 |
| Metric | TRST | ABUS |
|---|---|---|
| Price | $47.57 | $4.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 67.9K | ★ 2.0M |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | 26.46 | ★ 55.26 |
| EPS | ★ 3.25 | N/A |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $239.71 |
| P/E Ratio | $14.58 | ★ N/A |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $30.17 | $3.04 |
| 52 Week High | $48.45 | $5.10 |
| Indicator | TRST | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 55.41 |
| Support Level | $44.46 | $4.19 |
| Resistance Level | N/A | $4.64 |
| Average True Range (ATR) | 1.27 | 0.18 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 100.00 | 67.57 |
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company derives revenue from the business of Banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.